Advanced glycation end products (AGEs) are a cohort of heterogeneous compounds that
are formed after the nonenzymatic glycation of proteins, lipids and nucleic acids …

The size, heterogeneity, and biological production process of protein therapeutics like
monoclonal antibodies create unique challenges for their analysis and regulation compared …

Nonenzymatic glycation of macromolecules, especially proteins leading to their oxidation is
increased in diabetes mellitus due to hyperglycemia and play an important role in …

In diabetic patients, accelerated glycation process causes increased oxidative stress and
chronic hyperglycaemia that play a vital role in the diabetic complications. Extensive …

Nonenzymatic glycosylation or glycation of macromolecules, especially proteins leading to
their oxidation, play an important role in diseases. Glycation of proteins primarily results in …

Incubation of proteins with glucose lead to their non-enzymatic glycation ultimately resulting
in the formation of advanced glycation end products (AGEs) in vivo. AGEs alter unique three …

AIMS: To study the immunogenicity of advanced glycation end product (AGE) modified IgG
(AGE-IgG) in experimental animals. MAIN METHODS: Human IgG was subjected to in vitro …

Reactive carbonyl species (RCS) mainly reacts with lysine and arginine residues of proteins
to form advanced glycation end products (AGEs). Histone was glycoxidated with glyoxal and …

Nonenzymatic glycation of macromolecules, especially proteins, takes place mainly due to
hyperglycemia in diabetes mellitus. Increased glycolysis during cancer and inflammation …

Post translational modifications (PTMs) alter the characteristic properties of proteins by
influencing the spatial orientation of amino acid residues leading to a variety of pathological …